Microbot Medical Inc stock (US5950101098): LIBERTY call and Q1 2026 numbers keep focus on robot-assisted surgery

Microbot Medical Inc plans an analysts and investors call on May 18 to discuss the LIBERTY Endovascular Robotic System’s full market release, days after reporting Q1 2026 results. The small-cap medtech remains in the spotlight of the vascular robotics race.

Microbot Medical Inc is drawing fresh attention from investors after announcing an analysts and investors conference call for May 18 to review recent progress with the Full Market Release of its LIBERTY Endovascular Robotic System and to address what it calls misrepresentations in a third-party article, according to a GlobeNewswire release distributed on May 15, 2026 and carried by Business Insider as of 05/15/2026.

The conference call is set for Monday, May 18 at 3:00 p.m. Eastern Time and will feature Microbot Medical’s executive team together with current users of the LIBERTY system, who are expected to share clinical and practical experience with the technology in real-world endovascular procedures, according to the same May 15 announcement distributed via GlobeNewswire and referenced by StockTitan as of 05/15/2026.

Microbot Medical also recently reported its results for the first quarter of 2026, posting a net loss per share of minus 0.05 US dollars, which was better than the consensus forecast of minus 0.08 US dollars, while quarterly revenue came in at approximately 0.11 million US dollars versus expectations of 0.30 million US dollars, according to the earnings overview on MarketBeat as of 05/15/2026.

As of: 16.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Microbot Medical Inc
• Sector/industry: Medical devices / robotic-assisted surgery
• Headquarters/country: Hingham, Massachusetts, United States
• Core markets: United States and other markets for endovascular and interventional procedures
• Key revenue drivers: LIBERTY Endovascular Robotic System and related solutions
• Home exchange/listing venue: Nasdaq Capital Market (ticker: MBOT)
• Trading currency: US dollar (USD)

Microbot Medical Inc: core business model

Microbot Medical Inc focuses on developing and commercializing robotic systems designed to assist physicians during minimally invasive endovascular and other interventional procedures, using a compact, disposable architecture aimed at improving precision and safety in the cath lab environment, as described on the company’s corporate site in its general overview on Microbot Medical website as of 05/2026.

The company’s flagship technology is the LIBERTY Endovascular Robotic System, a remote-controlled robotic platform intended to enable physicians to manipulate guidewires and microcatheters from a shielded workstation, with the goal of reducing radiation exposure and physical strain while maintaining fine control of instruments inside blood vessels, according to product descriptions and investor materials provided on the company’s site and summarized by Microbot investor relations as of 05/2026.

Unlike some large-cap peers that offer fixed, capital-intensive robotic platforms, Microbot Medical emphasizes a smaller, potentially more flexible footprint and a single-use approach, aiming to lower barriers to adoption in community hospitals and outpatient centers compared to large, installed-base dependent systems, a theme that the company has highlighted in several presentations and written communications to shareholders referenced on its investor relations pages in 2025 and 2026.

From a business-model perspective, Microbot Medical seeks to combine upfront system placement with recurring revenue from procedure-based disposables, creating an installed base that can generate consumables revenue once LIBERTY systems are deployed at customer sites, a structure broadly consistent with other procedure-driven device companies and discussed in the firm’s historical filings with the SEC noted on its investor relations platform in filings through 2025.

Because Microbot Medical is still in the early stages of commercialization, current financials remain dominated by research and development expenses and commercialization costs rather than mature product revenue, with the company reporting a recorded net income of approximately minus 13.14 million US dollars and trailing earnings per share of about minus 0.29 US dollars over the last four quarters, according to data compiled on MarketBeat as of 05/15/2026.

Main revenue and product drivers for Microbot Medical Inc

The primary revenue driver for Microbot Medical is expected to be the LIBERTY Endovascular Robotic System, which is positioned for use in a range of vascular and interventional procedures including potentially peripheral vascular interventions and other endovascular applications, depending on regulatory clearances and clinical adoption, according to the product positioning outlined in the company’s technology descriptions on Microbot Medical website as of 05/2026.

The LIBERTY system’s Full Market Release is a key milestone, and it is this stage that will be in focus during the May 18 analysts and investors call, where management plans to review recent commercial progress, including experience from early users, and to clarify public information about the company and its product following what Microbot Medical has described as misrepresentations in a recent unaffiliated article, according to the May 15, 2026 GlobeNewswire release carried by Business Insider as of 05/15/2026.

In the latest reported quarter, Microbot Medical recorded revenue of about 0.11 million US dollars, reflecting the early stage of the commercial rollout and lower than the roughly 0.30 million US dollars that analysts had been expecting for the same period, a gap that underscores how adoption ramp and procedure volumes can fluctuate significantly in the early phase of a new platform’s deployment, as documented on MarketBeat as of 05/15/2026.

Despite the revenue shortfall in the first quarter of 2026, the company’s loss per share of minus 0.05 US dollars still surpassed consensus forecasts by 0.03 US dollars, reflecting cost control and the timing of operating expenditures, while MarketBeat’s compiled estimates suggest that Wall Street continues to model a full-year loss per share of approximately minus 0.34 US dollars, highlighting that Microbot Medical is still in a loss-making investment phase as of mid-2026, based on the same MarketBeat earnings summary accessed in May 2026.

Looking back at earlier quarters gives additional context: for the quarter ending June 2024, Microbot Medical reported a per-share loss of around minus 0.17 US dollars, which exceeded the Zacks Consensus Estimate for that period, illustrating that quarterly EPS can swing meaningfully as the company adjusts spending on research, regulatory processes and commercial infrastructure, according to the earnings recap on Zacks as of 06/20/2025.

Over the medium term, Microbot Medical’s potential revenue trajectory will largely hinge on the pace at which hospitals and interventional labs adopt LIBERTY, the number of procedures carried out per system, and the recurring revenue contribution from single-use components, all of which are typical drivers for robotic-assisted procedure platforms and are key themes in the company’s presentations and filings summarized across its investor relations communications in 2025 and 2026.

Industry trends and competitive position

The medical robotics and image-guided intervention market has been expanding as clinicians seek tools that can increase precision, reduce complication rates and lower occupational exposure to radiation, a trend supported by industry research from various market-analytics firms that highlight mid- to high-single-digit annual growth for interventional vascular procedures and associated robotics through the mid-2020s, as reported by multiple sector overviews on major healthcare technology news outlets during 2024 and 2025.

Within this space, Microbot Medical competes with larger diversified device manufacturers that offer vascular robotics solutions, as well as newer entrants, but differentiates itself by targeting a compact, potentially cost-efficient configuration and by promoting single-use robotic components, a strategy aimed at enabling hospitals to add robotics capabilities without the capital outlays associated with traditional large consoles, according to the positioning the company presents in investor decks and summaries available via its investor relations webpages as of 2025 and 2026.

Regulatory pathways, reimbursement frameworks and the accumulation of clinical data remain critical industry-wide factors, and Microbot Medical, like its peers, must navigate these elements to broaden adoption, with its announcements over the last two years emphasizing progress on approvals, user training and collaboration with early adopters, themes that are likely to be revisited during the May 18 LIBERTY progress call highlighted in the May 15, 2026 GlobeNewswire communication cited by StockTitan as of 05/15/2026.

Why Microbot Medical Inc matters for US investors

For US investors, Microbot Medical offers exposure to the theme of robotic-assisted vascular and interventional procedures through a Nasdaq-listed small-cap stock, which may react sensitively to clinical milestones, commercial updates and capital-market transactions, given the company’s development-stage profile and limited revenue base, as reflected in the modest first-quarter 2026 revenue and ongoing net losses summarized by MarketBeat as of 05/15/2026.

Because Microbot Medical trades on the Nasdaq Capital Market under the ticker MBOT and uses the US dollar as its primary trading currency, it is directly accessible to many US retail and institutional investors, who may follow not only quarterly earnings but also regulatory updates, hospital contracts and conference presentations as key catalysts, making the May 18 conference call a relevant near-term event for understanding the trajectory of the LIBERTY rollout and the management’s response to recent external commentary, according to the May 15, 2026 call announcement distributed via GlobeNewswire and cited by Business Insider as of 05/15/2026.

From a portfolio-construction standpoint, Microbot Medical represents a focused bet on a specific device platform rather than a diversified exposure to the broader medical technology sector, and the stock’s performance can therefore diverge significantly from larger healthcare indices depending on trial results, reimbursement decisions, financing developments and take-up of the LIBERTY system in US and potentially international markets, dynamics that investors have seen play out in other early-stage medtech names on US exchanges over recent years.

Conclusion

Microbot Medical Inc is entering a pivotal phase as it advances the Full Market Release of its LIBERTY Endovascular Robotic System and prepares to address investors and analysts in detail on May 18, only days after reporting first-quarter 2026 results that showed a narrower loss per share than expected but revenue still at an early stage level, according to the earnings summary on MarketBeat in mid-May 2026 and the conference call announcement distributed via GlobeNewswire and cited by Business Insider on May 15, 2026. The stock’s future path is likely to depend heavily on the pace of LIBERTY adoption, the strength of real-world user feedback, regulatory and reimbursement developments and the company’s ability to manage funding needs, making Microbot Medical a focused, higher-risk exposure within the US-listed medical device and robotics universe rather than a broad-based healthcare holding, and investors will be watching the upcoming call for additional color on strategy, commercialization and responses to recent external commentary.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.